BALAXI PHARMACEUTICALS LIMITED — Important, 05-03-2025: Updates

Balaxi Pharmaceuticals Limited submitted their unaudited financial results for the quarter and nine months ended December 31, 2024. The standalone results show total income of ₹563.92 crore, with ₹513.94 crore from operations and ₹50.53 crore in other income. Expenses amounted to ₹499.66 crore, leading to a profit before tax of ₹64.27 crore. The net profit stands at ₹47.81 crore, translating to an Earnings Per Share (EPS) of ₹0.87. Consolidated results indicated total income of ₹2,142.72 crore and net profit of ₹164.33 crore, yielding an EPS of ₹2.98. The board meeting also approved the remuneration for the Managing Director for the remaining tenure, subject to shareholder approval through postal ballot. Investors should take note of the solid financial performance shown, highlighting potential growth and a positive outlook in the pharmaceutical sector.